# Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia

> **NCT04578210** · PHASE1,PHASE2 · COMPLETED · sponsor: **Instituto de Investigación Hospital Universitario La Paz** · enrollment: 84 (actual)

## Conditions studied

- Corona Virus Infection

## Interventions

- **BIOLOGICAL:** T memory cells and NK cells

## Key facts

- **NCT ID:** NCT04578210
- **Lead sponsor:** Instituto de Investigación Hospital Universitario La Paz
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-04
- **Primary completion:** 2022-01-13
- **Final completion:** 2022-03-30
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578210, "Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04578210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*